Thelma Rose Simon, LADC, BSW Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 112 North Reservation Road, Fort Mcdermitt Indian Health Service, Mcdermitt, NV 89421 Phone: 775-532-8522 Fax: 775-532-8024 |
Mrs. Beverly Ann Shell, LPN-NURSE Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: Fort Mcdermitt Wellness Center, Suite 702g, Mcdermitt, NV 98421 Phone: 775-532-8522 Fax: 775-575-2384 |
News Archive
Grand Challenges Canada announces a grant today to support further development of a new innovative device to attract and kill mosquitoes that can transmit malaria.
BioInvent International AB today announces IND clearance from the U.S. Food & Drug Administration (FDA) to initiate a Phase II study for BI-204. BI-204 is a human monoclonal antibody that specifically targets oxidized forms of a low-density lipoprotein (LDL) which has been linked to increased inflammatory processes leading to plaque formation in the blood vessel walls. BI-204 is being co-developed with Genentech for secondary prevention of cardiovascular events in patients with acute coronary syndrome (ACS).
When a song on the radio or the cell phone on the car seat next to a young driver beckon, she may not resist the temptation to turn up the dial or take a call while maneuvering in traffic.
Manhattan Pharmaceuticals, Inc. announced that on January 4, 2011, the company entered into a settlement and release agreement with Nordic Biotech Fund II K/S and H Pharmaceuticals K/S. Manhattan Pharmaceuticals and Nordic are partners in the H Pharmaceuticals joint venture for the development and commercialization of HedrinĀ®, a non-pesticide treatment for head lice.
› Verified 7 days ago